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Summary
Paget’s disease of bone (PDB) is a metabolic bone disease
characterized by excessive bone resorption and formation
due to increased osteoclasts activity. PDB mostly runs
asymptomatically, although increased bone turnover can be
present and in approximately 30% of patients bone abnormali-
ties, such as bone pain and deformities, pathological fractures
and deafness may occur. The existence of familial aggrega-
tion of PDB has been reported in numerous papers, describ-
ing the occurrence of disease in successive generations. It
has been clearly established that PDB is genetically heteroge-
neous with several loci able to confer an increased suscepti-
bility to develop this bone metabolic disorder. In particular,
the PDB3 locus in chromosome 5q35-qter hosts the sequesto-
some1/p62 (SQSTM1/p62) gene whose mutations account for
most of the sporadic and familial forms of PDB reported in lit-
erature. SQSTM1/p62 gene encodes the SQSTM1/p62 protein,
component of the NF-kB signaling pathway and mediating in-
tracellular signaling from IL-1/TNF toward NF-kB, crucial for
osteoclast differentiation and activity. A functional study sug-
gests that the S Q S T M 1 mutation may predispose to PDB af-
fecting the interaction between SQSTM1/p62 protein and a
hitherto unidentified protein(s) modulating the bone turnover,
but the underlying molecular mechanism need to be elucidat-
ed. However, independently from the knowledge of the func-
tional aspects of S Q S T M 1 / p 6 2 mutation, the opportunity to
perform germline mutational analysis in PDB patients may be
helpful in detecting new genetic carriers in potentially familial
forms of PDB and in studying the co-segregation of such DNA
variants with the PDB phenotype. All together these studies
could open new possibilities in the prevention and therapy of
PDB and of other metabolic bone disorders.
KEY WORDS: Paget’s disease of bone, genetics, SQSTM1/p62 gene, muta -
tional analysis.
Introduction
Several evidences reported in literature support the important
of genetics in the pathogenesis of Paget’s disease of bone
[PDB; MIM 602080]: a) the maintenance of the hereditary pat-
tern after the emigration (1); b) a positive familial history of
PDB in affected members from multigenerational pedigrees (1-
3); c) approximately 15 to 40% of index cases has at least one
first degree relative affected by PDB (1, 4) and in a large num-
ber of multigenerational affected pedigrees the disease exhibits
a dominant autosomal pattern of inheritance, although a male
to male transmission has been also described (5). 
Other clinical entities have been reported to be correlated to
the clinical phenotype of PDB, in particular Familial Expansile
Osteolysis [FEO; MIM 602080, 174810], characterized by simi-
lar histological features, presence of viral-like inclusions in af-
fected osteoclasts and earlier age at onset respect to the one
of “classic” PDB, and Expansile Skeletal Hyperphosphatasia
[ESH; MIM 602080] that differs from both PDB and FEO (6). Fi-
nally, an early onset familial PDB variant has been originally re-
ported in one family (7, 8), and it could be regarded as a vari-
ant of common PDB, differing for some clinical parameters.
These PDB correlated syndromes are specifically treated in an-
other chapter in this issue of the Journal.
Thus, PDB is genetically heterogeneous with at least 7 genet-
ic loci (P D B 1 - P D B 7) initially reported to be associated to a
higher susceptibility’s risk to develop the disease (Table I). In
particular, P D B 1 and P D B 2 loci involvement seems to be re-
stricted to only few families (9, 10), whereas mutations of
P D B 3 locus has been reported to be a common cause of both
sporadic and familial PDB cases in populations of different
ethnic origin (11-17). Since controversial findings have been
reported for the role of P D B 1 locus into PDB pathogenesis
(18, 19), we consider only six possible candidate loci identi-
fied so far (P D B 2 - 7) by genome-wide searches. This review
will be particularly focused on the role that P D B 3 locus plays
in the pathogenesis of PDB.
P D B 2 locus encodes a member of the Tumor Necrosis
Factor Receptors Superfamily: RANK (TNFRSF11A) gene.
FEO, ESH and early onset PDB phenotypes
Mutations of TNSFR11A gene, located at human chromosome
18q21, have been reported to cause three different distinct clin-
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Table I - PDB is a genetically heterogeneous disorder.
Chromosome Gene
6p HLA-PDB1
18q21.2-21.3 TNFSR11A-PDB2
5q35 SQSTM1-PDB3
5q31 PDB4
2q36 PDB5
10q13 PDB6
18q23 PDB7
9p21.1-q12 (?)
FOR
 REV
IEW 
ONL
Y
© CI
C ED
IZION
I INT
ERN
AZIO
NALI
ical familial syndromes, although partially overlapping, resem-
bling common PDB to a vary extent. Specifically, the mutations
consist of three different insertions (duplications), located at ex-
on 1 of the gene, affecting the signal peptide of RANK: a)
84dup18 bp accounts for FEO phenotype (7, 20, 21); b)
84dup15 bp for ESH phenotype (20, 22); and c) 75dup27 caus-
es early onset familial PDB (7). In vitro analysis demonstrated
that 84dup18 bp and 75dup27 insertions affect the normal pro-
teolytic cleavage of the RANK signal peptide with consequent
reduction in the amount of RANK protein and similar degree of
the transcription factor nuclear factor kB (NFkB) activation
(23). NFkB is essential in the molecular pathway to osteoclas-
togenesis and/or osteoclast activation (12).
Mutations of T N S F R 1 1 A gene seems to be restricted to only
few affected families and several reports failed to detect both
positive linkage and mutations in sporadic and familial forms of
PDB. In fact, linkage to 18q21 loci is not frequent in familial
PDB (12, 24, 25) and no significant association between TNS -
FR11A gene polymorphisms and sporadic PDB has been de-
scribed (7).
PDB3 locus encodes the SQSTM1/p62 protein: an ubiqui -
tin-binding protein
S Q S T M 1 / p 6 2 protein has been shown to play an important
role as a scaffold protein leading to the activation of NFkB
(26), important factor for recruitment of pre-osteoclasts and
maturation of osteoclastic cells. Mutational analyses of
S Q S T M 1 / p 6 2 gene, located at human chromosome 5q35,
originally performed in French-Canadian and British pedi-
grees, identified it as the PDB3 locus, accounting for the most
of both sporadic and familial PDB cases (11-17). All the
S Q S T M 1 / p 6 2 mutations reported in literature, either in spo-
radic or familial PDB cases, are within exons 7 and 8 encoding
the ubiquitin-binding associated domain (UBA) (26).
S Q S T M 1 / p 6 2 protein has the ability to no covalently bind mul-
ti-ubiquinated chains through amino acids 386-434 in the C
terminus of the protein (Figure 1), maybe storing ubiquinated
proteins. As reported above, sequestosome1 is a scaffold pro-
tein in both the TNFa and interleukin 1 pathway leading to a
selective activation of NFkB (26).
More than ten different S Q S T M 1 / p 6 2 gene mutations, acting
through a dominant negative manner, have now been widely re-
ported in PDB affected subjects from ethnically different popula-
tions, strongly confirming its role into pathogenesis of sporadic
and familial form of PDB (Figure 2). In particular, amino acidic
substitution of a proline residue with a leucine residue at codon
392 (P392L), at exon 8, is the most frequently S Q S TM 1 / p 6 2 d e-
scribed mutation in PDB cases (11-17) (Table II). In general,
SQSTM1 missense mutations are mostly represented than non-
sense mutations and, although the latter determine a truncated
protein, no clear difference in genotype/phenotype correlation, in
term of age at onset and skeletal extent of PDB, has been estab-
lished (14). In fact, recently, Hocking et al. performed an elegant
functional and structural analysis of three widely report missense
mutations at UBA domain of S Q S T M 1 / p 6 2 gene (14): P392L,
M404V (methionine to valine substitution at codon 404) and
G425R (glycine to arginine substitution at codon 425). They
found S Q S T M 1 / p 6 2 mutations in approximately 38% of the PDB
families analyzed: 30% missense mutations and approximately
8% truncating mutations. No S QS T M 1 / p 6 2 mutations were re-
ported in the remaining 62% of PDB families. In general, these
Authors observed that PDB exhibiting S Q S T M 1 / p 6 2 gene muta-
tions could have a precocious age at onset and a more extent
disease than nonmutant PDB subjects. More specifically, their
statistical approach, although not significant, revealed a tenden-
cy to a more extent skeletal involvement and an earlier onset of
PDB in affected subjects with truncating mutations (14). Howev-
er, although this work confirms the importance of UBA domain-
specific mutations of S Q S T M 1 / p 6 2 as a cause of PDB, it sug-
gests that whatever the S QS T M 1 / p 6 2 mutation it predisposes to
PDB independently from affecting the binding properties to ubiq-
uitin, but rather it may involve interaction between S Q S T M1 / p 6 2
protein and a hitherto unidentified protein(s) modulating the bone
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Figure 1 - Domains organization of the S Q S T M 1 / p 6 2 protein. All the
SQSTM1/p62 mutations reported in literature are within exons 7 and 8
encoding the ubiquitin-binding associated domain (UBA). For further
details see Geetha T, Wooten MW.J Biol Chem. 2003 [ref. 26].
Figure 2 - UBAmutations reported in literature.See references 11-17.
Table II - SQSTM1/p62 P392L mutation is the most frequent.
Described in:
French-Canadian
Italy
Australia / Geelong
Australia / Perth
Hungary / Budapest
New Zeland / Auckland
UK / North and SouthEngland
UK /Scotland
USA
The Netherlands
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t u r n o v e r .
Considering the isolated UBA domain functioning as a compact
monomer it may explain the hypothetical effects of the muta-
tions on polyubiquitin binding. Both the P392L and G411S mu-
tations seem to have light local effects on secondary structure
of UBA that could be particularly relevant in full-length
S Q S T M 1 / p 6 2 protein. Further studies to identify the in vivo
ubiquitylated substrates of SQSTM1/p62 will add important in-
formation to assess the functional significance of the
SQSTM1/p62-ubiquitin interaction and, consequently the dis-
ease-associated mutations.
Importance of the S Q S T M 1 / p 6 2 gene mutational analysis
in clinical practice
All the reports appeared in international literature clearly indi-
cate an autosomal pattern of inheritance of familial PDB (11-
17) with most of the affected subjects having a SQSTM1/p62
mutation and several asymptomatic gene mutant carriers in
last generations. Thus, mutational analysis in sporadic index
case of PDB may be helpful to detect new PDB families, espe-
cially in small size pedigrees and/or in family without an appar-
ent familial aggregation of PDB. In particular, in generations
with young members (below the threshold age of onset of 55
years commonly established for clinical expression of “classic”
PDB) asymptomatic gene mutant carrier(s) could be detected,
providing the opportunity to perform an accurate clinical follow-
up of these subjects in order to precociously detect the onset of
the first PDB-related sign/symptom. Good et al. and Eekhoff et
al. suggest to evaluate the circulating levels of alkaline phos-
phatase (AP) in asymptomatic carriers, also beneficing the low
cost and the wide availability of such test (15, 16). More specif-
ically, Eekhoff et al. wrote that “initial screening for serum AP
activity followed by bone scintigraphy only when the serum AP
activity is elevated can identify Paget’s disease in 1 of 5
screened family members of patients with familial disease. This
rate of detection of the disease increases further when only
subject who are older than 40 years undergo imaging studies”
(16). Unfortunately, we have to consider that PDB exhibits an
incomplete penetrance that may limit the efficacy and the ad-
vantages of both genetic and biochemical tests.
Incomplete penetrance and variable expression of PDB:
major pitfalls in genetic analysis of both sporadic and fa-
milial forms of PDB
Several Authors have reported an incomplete penetrance of
PDB clinical expression in members from PDB families with
known SQSTM1/p62 mutation. We briefly summarize four ma-
jor conditions of incomplete penetrance: 1) affected individuals
from PDB family with know SQSTM1/p62 mutation do not ex-
hibit the segregating mutation (11-15); 2) subjects from a PDB
family with known SQSTM1/p62 mutation share the same mu-
tation of affected members but they do not have PDB clinical
expression, although they are older than 55 years of age (13);
3) S Q S T M 1 / p 6 2 mutant individuals from a PDB family with
known S Q S T M 1 / p 6 2 mutation carry the mutation but they do
not have PDB clinical expression. It may be due to their
younger age (13, 16). Moreover, it should be also considered
that, differently from older PDB affected, youngest carriers may
have not had a long term exposure to rural environment and/or
measles infection because of massive vaccination campaigns
(started in 1963 in the United States of America); and 4) PDB
is a genetically heterogeneous disorder with many families ex-
hibiting incomplete penetrance and variable expression. All that
indicates PDB to be a poligenic trait, with a possible second hit
occurring in a modifying gene, partly explaining the lack of pen-
etrance observed in carrier members from affected families. In
particular, the possible role of modifying genes, able to control
the PDB clinical expression in S Q S T M 1 / p 6 2 mutant carriers,
has been recently postulated for P D B 2 - R A N K gene and the
still unknown PDB7 locus (13-15). Johnson-Pais et al. describe
a family with positive linkage to chromosome 18q21 region in-
cluding RANK gene co-segregating with a SQSTM1/p62 muta-
tion in affected subjects (13). Thus, they hypothesized the exis-
tence of a possible dual modifying interaction among R A N K
and S Q S T M 1 / p 6 2 genes. Conversely, Good et al. previously
reported in a branch of a large PDB pedigree a positive linkage
to 18q23 loci (PDB7) associated to an early onset of PDB (27).
Lately, they found that this large family also exhibited a signifi-
cant linkage to the 5q35 region that harbors the SQSTM1/p62
gene. Subsequently, SQ S T M 1 / p 6 2 mutational analysis re-
vealed the presence of L394X truncating mutation segregating
with all, but three, PDB affected members and within the
branch exhibiting early PDB onset (PDB7). Thus, Authors hy-
pothesized that the still unknown PDB7 locus may harbor a
gene modulating the age at onset of PDB (27).
Other PDB susceptibility’s gene(s)
Another rare syndrome related to PDB, named juvenile Paget’s
disease, has been described to be caused by inactivating muta-
tions of the T N F R S F 1 1 B gene on 8q24 (28). This gene en-
codes osteoprotegerin (OPG). It has been well established that
OPG plays a critical role in the regulation of osteoclast forma-
tion and bone resorption (29). OPG is a member of the TNF re-
ceptor superfamily acting as a physiological regulator of bone
turnover by competitively binding to RANKL and preventing
RANKL-induced activation of RANK on osteoclasts and osteo-
clast progenitors (30). Interestingly, mice over expressing OPG
develop osteopetrosis secondary to the failure of osteoclast for-
mation (31), whereas mice with targeted inactivation of OPG
develop osteoporosis and bone fractures caused by increased
bone turnover (32). In previous studies, mutations of both OP G
and R A N K genes have been excluded as a common cause of
PDB (33, 34) but several polymorphisms of T N F R S F 1 1 B g e n e
have been identified (34, 35). Some evidences suggest that al-
lelic variation at the T NF R S F 1 1 B locus could be associated with
PDB (34, 36). In a small case-control study on Belgian PDB pa-
tients an association between a single nucleotide polymorphism
(SNP) in intron 2 and sporadic PDB has been described (34). 
In literature, individuals with loss-of-function mutations and
deletions affecting the T N F R S F 1 1 B gene have been de-
scribed. They develop the syndrome of idiopathic hyperphos-
phatasia or juvenile Paget’s disease, a rare disorder presenting
in infancy or childhood with increased bone turnover, progres-
sive bone deformity, bone fractures, and deafness (20, 28).
Recently, a study on British descent PDB cases reveal a signif-
icant association between the TNFRSF11B G1181C polymor-
phism, at exon 1, and both sporadic and familial PDB (37). The
G1181 allele is over-represented in subjects with PDB, consis-
tent with a dominant effect of G1181 on PDB susceptibility. In a
previous study the same “G” allele at position 1181 was over-
represented in Danish osteoporotic fracture patients when
compared with controls (35). All these findings strongly suggest
that the “G” allele may predispose to an increased bone
turnover. The increased risk for PDB reported in the paper by
Da oszewska et al. was not as high as the one described in in-
dividuals with a first-degree relative affected with PDB (1) sug-
gesting that the G1181C polymorphism may represent only
one of the several factors contributing to the susceptibility to
PDB. In order to reduce the possibility of false positive results
t at in association studies are caused by population stratifica-
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tion, the Authors also performed a family-based study and re-
ported the evidence of transmission disequilibrium of T N -
F R S F 1 1 B alleles in subjects with a positive family history of
PDB. Such polymorphism determines the lysine to asparagine
substitution. Thus, Authors (37) speculated that the change
from a positively charged lysine to an uncharged, polar as-
paragine in the hydrophilic N-region of the signal peptide of
OPG may affect targeting and membrane insertion during OPG
transport through the cytosol, potentially leading to an imbal-
ance in availability of OPG in bone microenvironment, espe-
cially in locally stimulated increased bone turnover conditions,
such as repetitive mechanical loading, trauma, viral infections,
reduced calcium intake, or a combination of these factors (38-
40). However, such hypothesis need further deep evaluation to
be confirmed.
Conclusions
PDB is a quite common condition with a strong heterogeneous
genetic component. Mutations affecting the UBA domain of
S Q S T M 1 / p 6 2 gene have been demonstrated to be an impor-
tant cause of the disease (11, 12). However, in a functional
study none of the analyzed missense mutations showed to af-
fect the folding of the UBA domain (14). In particular, the
M404V and G425R mutations have been predicted to affect the
hydrophobic patch of the UBA domain binding ubiquitin in sub-
tly different ways by either modifying the van der Waals surface
contours (M404V) or by placing a highly polar side chain in the
middle of the hydrophobic patch (G425R) consistent with the
loss of ubiquitin chain-binding (14). Moreover, the G411S mu-
tation, far from the hydrophobic patch, does not perturb ubiqui-
tin chain binding. Although the clustering of the PDB-causing
mutations in the UBA domain of SQSTM1/p62 suggest that the
mutant proteins cause PDB by affecting the ability of
SQSTM1/p62 to bind ubiquitin, a clear correlation between the
ability of the mutant UBA domain to bind polyubiquitin and the
presence or extent of PDB has not been demonstrated. Thus,
the mutations of SQSTM1/p62 may cause PDB not dependent-
ly on the polyubiquitin binding properties of the mutant UBA do-
main. Mutations at the UBA domain may determine a selective
loss of binding to a specific ubiquitylated substrate as suggest-
ed by the ubiquitin-binding experiments conducted with unan-
chored ubiquitin chains (14). However, it cannot be excluded
that SQSTM1/p62 mutations may affect the overall structure of
the related holoprotein, thereby affecting its half-life or other
protein-protein interactions. Finally, the SQSTM1/p62 UBA do-
main may interact with non-ubiquitylated substrates affecting
the bone cell activity and its mutations may alter this interac-
tion.
The OPG polymorphism found to be associated with both spo-
radic and familial PDB indicates the T N F R S F 1 1 B gene as a
susceptibility gene for PDB, as well as the causal gene for the
rare PDB-like syndrome of idiopathic hyperphosphatasia/juve-
nile Paget’s disease (37). However, more association studies
on large PDB populations from different Countries need to be
performed in order to confirm the role of this gene in conferring
susceptibility to PDB. Moreover, both wide genome linkage
analysis in multigenerational PDB pedigrees and candidate
gene approach will be extremely important to discover and/or
confirm the existence of new PDB susceptibility genes.
Although genetic factors have been thoroughly investigating, it
is important to take in mind that environmental factors, such as
rural environment or viral infections, have also been implicated
in the pathogenesis of PDB. In fact, the possibility that PDB
arises as the result of a chronic infection of osteoclast precur-
sors with paramyxoviruses still await for further elucidations
(38-40). According to recent findings in the field of molecular
g netics of PDB it can be speculated that viral proteins might
interact with the mutant forms of SQSTM1/p62 to stimulate os-
teoclast formation.
N w molecular strategies, such as the ones offered by the
“omic” technologies, will be helpful to genetically dissect the
PDB pathogenesis. A better knowledge on the role that gene
mutations and polymorphisms may play in the pathophysiology
of PDB and bone cells function will be extremely important in
order to: a) identify their effects on skeletal metabolic disor-
ders; b) develop new therapeutical strategies.
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